Key result
Mitral bioprostheses show comparable 10-year mortality versus mechanical valves in dialysis patients.
Why the study?
Late outcomes comparing mechanical and bioprostheses after isolated mitral valve replacement in dialysis-dependent patients had not been established.
Does mitral bioprosthesis compared to mechanical prosthesis improve long-term outcomes in dialysis-dependent patients undergoing isolated mitral valve replacement?
Cohort
Yes
Does mitral bioprosthesis compared to mechanical prosthesis improve long-term outcomes in dialysis-dependent patients undergoing isolated mitral valve replacement?
Mean Difference: -0.03
Absolute Event Rate: 15.45% vs 14.54%
In dialysis patients undergoing mitral valve replacement, bioprosthetic and mechanical valves provide similar long-term survival, though bioprostheses carry a slightly higher risk of reoperation.
Comparable mortality supports either valve type in dialysis mitral replacement; leaves open need for randomized data on reoperation and durability.
BACKGROUND: To compare the late outcomes between mechanical and bioprostheses after isolated mitral valve replacement (MVR) in dialysis-dependent patients. METHODS: A nationwide propensity-matched retrospective cohort study was conducted involving dialysis patients who underwent primary mitral replacement between 2001 and 2018. Ten-year postoperative outcomes were compared between mitral bioprosthesis and mechanical prosthesis using the Cox proportional hazard model and restricted mean survival time (RMST). RESULTS: The all-cause mortality was 20.8 and 13.0 events per 100 person-years, with a 10-year RMST of 7.40 and 7.31 years for bioprosthesis and mechanical prosthesis, respectively. Major bleeding was the most common adverse event for both bioprosthesis and mechanical prosthesis, with an incidence rate of 19.5 and 19.1 events per 100 person-years, respectively. The incidence of valve reoperation was higher among those who received bioprosthesis (0.55 events per 100 person-years). After 1:1 matching, the all-cause mortality was 15.45 and 14.54 events per 100 person-years for bioprosthesis and mechanical prosthesis, respectively. The RMST at 10 years was comparable between the two groups after matching (5.10 years for bioprosthesis vs. 4.59 years for mechanical prosthesis), with an RMST difference of -0.03. Further, no difference was observed in the incidence of major adverse valve-related events between bioprosthesis and mechanical valves. However, bioprosthesis was associated with a higher incidence of mitral valve reoperation among all major adverse events (RMST difference -0.24 years, 95% CI -0.48 to -0.01, P =0.047). CONCLUSIONS: This study found no association between valve selection and long-term survival outcomes in dialysis patients after MVR. However, bioprosthetic valves may be associated with a slightly higher incidence of reoperation, while other valve-related adverse events, including major bleeding and stroke, were comparable between the two types of prostheses.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) conducted a cohort in Dialysis-dependent patients requiring isolated mitral valve replacement. Mitral bioprosthesis vs. Mechanical prosthesis was evaluated on All-cause mortality (RMST difference -0.03). In dialysis patients undergoing mitral valve replacement, bioprostheses and mechanical prostheses showed comparable 10-year all-cause mortality (15.45 vs 14.54 events per 100 person-years).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: